Datasets:
id stringlengths 11 11 | problem_number int64 1 20k | title stringlengths 51 333 | statement stringlengths 182 873 | clean_statement stringlengths 151 658 | plain_language_statement stringlengths 125 688 | background stringlengths 609 1.29k | question_type stringclasses 20
values | category_id stringclasses 20
values | category_num int64 1 20 | primary_category stringclasses 20
values | set_id stringclasses 40
values | is_gold_seed bool 2
classes | condition_name stringlengths 8 146 | population_description stringlengths 8 353 | question_framework_type stringclasses 9
values | intervention_or_focus stringlengths 4 223 | comparator_or_reference stringlengths 6 218 | time_horizon stringclasses 17
values | translational_stage stringclasses 9
values | evidence_state stringclasses 6
values | consensus_state stringclasses 3
values | difficulty_level_id int64 1 5 | research_difficulty stringclasses 5
values | status stringclasses 3
values | publication_class stringclasses 4
values | proposed_by stringlengths 87 182 | proposed_year int64 2.02k 2.03k | source_url stringlengths 29 60 | source_citation stringlengths 48 303 | active_trial stringlengths 73 168 | literature_papers_count int64 3 3 | total_sources_per_problem int64 5 5 | published bool 1
class |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UMED-000001 | 1 | Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2- Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy — Open Classification Question | Among adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, can a reproducible subphenotype taxonomy based on Consensus-Based risk stratification algorithm for HR+/HER2- early breast cancer to guide adjuvant CDK4/6i therapy resolve clinical heterogeneity an... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does Consensus-Based risk stratification algorithm compare with conventional clinicopathologic staging and consensus taxonomy regarding overall survival and progression-free or disease-free surviv... | In patients affected by early-stage hormone-receptor-positive HER2-negative breast cancer, what is the clearest medical evidence on whether Consensus-Based risk stratification algorithm works better than conventional clinicopathologic staging and consensus taxonomy over 60 months? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of development ... | classification | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | prognostic | Consensus-Based Risk Stratification Algorithm | Conventional clinicopathologic staging and consensus taxonomy | 60 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 2 | moderate | open | OPEN-VERIFIED | Mallavarapu KM et al., Jin X et al., Qureshi Z et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.2147/bctt.s620643 | Mallavarapu KM et al., Breast cancer (Dove Medical Press) (2026); DOI: 10.2147/bctt.s620643 | NCT03078751 (PHASE2, COMPLETED): Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Ca (SRC-MED-NCT-0003) | 3 | 5 | true |
UMED-000002 | 2 | Large B-cell lymphoma (LBCL) — Open Diagnosis Question | For adults with primary refractory or early relapsed DLBCL receiving CD19-directed CAR-T cell therapy in ambulatory specialty, laboratory or pathology care, can tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias reduce diagnostic delay and misclassification compared with standar... | In adults with primary refractory or early relapsed DLBCL receiving CD19-directed CAR-T cell therapy, how does tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias compare with standard pre-infusion clinical risk scores regarding overall survival and progression-free or disease-fr... | Can tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 24 months compared with standard pre-infus... | In oncology and hematology, managing diffuse large b-cell lymphoma relapsing after first-line chemoimmunotherapy (primary refractory or early relapse <=12 months) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Diffuse large B-cell lymphoma relapsing after first-line chemoimmunotherapy | Adults with primary refractory or early relapsed DLBCL receiving CD19-directed CAR-T cell therapy | PIRD | Tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias | Standard pre-infusion clinical risk scores (IPI and LDH) | 24 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Thieblemont C et al., Liu Z et al., Fu X et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,025 | https://doi.org/10.1002/hem3.70207 | Thieblemont C et al., HemaSphere (2025); DOI: 10.1002/hem3.70207 | NCT01410630 (OBSERVATIONAL, COMPLETED): FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma (SRC-MED-NCT-0019) | 3 | 5 | true |
UMED-000003 | 3 | Adherence of Oncologists and Cardiologists to Venous Thromboembolic Disease Prevention and Treatment Guidelines in Cancer Patients — Open Implementation Question | Among ambulatory specialty practices managing adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does structured clinical pathway integration of adherence of oncologists and cardiologists to venous thromboembolic disease preventio... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months compare with continued full-dose DOAC or weight-adjusted daltep... | Among individuals with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (including thrombocytopenia 25-50 x10^9/L, hepatic or renal dysfunction), does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months offer meaningf... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | implementation | Reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months | Continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin | 24 months | implementation | multiple_small_studies | specialist_consensus_open | 2 | moderate | partially_resolved | PARTIAL-PROGRESS | Turk UO et al., Kania J et al., Zhanghuang C et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.3390/jcm15124504 | Turk UO et al., Journal of clinical medicine (2026); DOI: 10.3390/jcm15124504 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000004 | 4 | Clinical Management of Acute Graft-Versus-Host Disease — Open Comparative Effectiveness Question | Across diverse clinical cohorts of children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD compare against extracorporeal ph... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD compare with extracorporeal photopheresis or calcineurin-inhibito... | What are the real-world benefits and risks of ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD versus extracorporeal photopheresis or calcineurin-inhibitor continuation over 24 months for patients managing steroid-refractory acute and chronic graft-versus-host disease after ... | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | Ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD | Extracorporeal photopheresis or calcineurin-inhibitor continuation | 24 months | comparative_effectiveness | systematic_review_low_certainty | active_scientific_dispute | 2 | moderate | contested | DISPUTED-OPEN | DeFilipp Z et al., Chalchal H et al., Arcuri LJ et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1016/j.jtct.2026.04.053 | DeFilipp Z et al., Transplantation and cellular therapy (2026); DOI: 10.1016/j.jtct.2026.04.053 | NCT04744116 (EARLY_PHASE1, RECRUITING): Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatmen (SRC-MED-NCT-0038) | 3 | 5 | true |
UMED-000005 | 5 | Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH) — Open Diagnosis Question | In patients with paroxysmal nocturnal hemoglobinuria (PNH) presenting for clinical evaluation, what is the diagnostic accuracy and clinical utility of diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) compared with conventional clinicopathologic, imaging, or laboratory reference standard for improvi... | In patients with paroxysmal nocturnal hemoglobinuria (PNH), how does diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding annualized bleeding or crisis rate, hemoglobin stabilization, and event-free surviva... | For people with paroxysmal nocturnal hemoglobinuria (PNH), how does diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) compare with conventional clinicopathologic, imaging, or laboratory reference standard for improving annualized bleeding or crisis rate, hemoglobin stabilization, and event-free surv... | In oncology and hematology, managing paroxysmal nocturnal hemoglobinuria (PNH) (clinically characterized human cohort) requires balancing annualized bleeding or crisis rate, hemoglobin stabilization, and event-free survival and thromboembolic events, hemolysis or bleeding breakthroughs, and immunogenicity. Studies of e... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Patients with paroxysmal nocturnal hemoglobinuria (PNH) | PIRD | Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH) | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | BLOCKED-OPEN | Fattizzo B et al., Liu H et al., Obara N et al. & National Academies of Sciences, Engineering, and Medicine (NASEM) Health and Medicine Division | 2,026 | https://doi.org/10.1111/ejh.70294 | Fattizzo B et al., European journal of haematology (2026); DOI: 10.1111/ejh.70294 | NCT06839456 (PHASE1/PHASE2, RECRUITING): Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/C (SRC-MED-NCT-0052) | 3 | 5 | true |
UMED-000006 | 6 | Assessment of Large Language Models in Colorectal Cancer Multidisciplinary Tumor Board Decision-Making — Open Implementation Question | In routine clinical practice for patients with colorectal cancer multidisciplinary tumor board Decision-Making, does a multifaceted implementation bundle for assessment of large language models outperform usual guideline dissemination without multifaceted implementation strategy in adoption, sustainment, and overall su... | In patients with colorectal cancer multidisciplinary tumor board Decision-Making, how does large language models compare with usual guideline dissemination without multifaceted implementation strategy regarding overall survival and progression-free or disease-free survival over 60 months? | In patients affected by colorectal cancer multidisciplinary tumor board Decision-Making, what is the clearest medical evidence on whether large language models works better than usual guideline dissemination without multifaceted implementation strategy over 60 months? | In oncology and hematology, managing colorectal cancer multidisciplinary tumor board Decision-Making (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of assessment of larg... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Colorectal Cancer Multidisciplinary Tumor Board Decision-Making | Patients with colorectal cancer multidisciplinary tumor board Decision-Making | implementation | Large Language Models | Usual guideline dissemination without multifaceted implementation strategy | 60 months | implementation | multiple_small_studies | broad_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Farzaliyeva A et al., Ito K et al., Shan H et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.3390/curroncol33060309 | Farzaliyeva A et al., Current oncology (Toronto, Ont.) (2026); DOI: 10.3390/curroncol33060309 | NCT06832917 (PHASE3, NOT_YET_RECRUITING): Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant (SRC-MED-NCT-0013) | 3 | 5 | true |
UMED-000007 | 7 | The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management in Early Breast Cancer — Open Rehabilitation Question | For adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy in ambulatory specialty rehabilitation pathways, does individualized therapy with the 11th korean breast cancer society consensus conference on axillary management produce durable gains in overall sur... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does the 11th korean breast cancer society consensus conference on axillary management compare with usual physical and functional care without structured rehabilitation pathway regarding overall s... | Can the 11th korean breast cancer society consensus conference on axillary management safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with usual physical and functiona... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of the 11th kor... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | PICOTS | The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management | Usual physical and functional care without structured rehabilitation pathway | 60 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 3 | hard | open | OPEN-VERIFIED | Bae SJ et al., Mallavarapu KM et al., Hannoun-Levi JM et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.4048/jbc.2026.0144 | Bae SJ et al., Journal of breast cancer (2026); DOI: 10.4048/jbc.2026.0144 | NCT06781281 (OBSERVATIONAL, RECRUITING): NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. (SRC-MED-NCT-0001) | 3 | 5 | true |
UMED-000008 | 8 | Tackling similarities and differences in global practice guidelines for gastric cancer — Open Implementation Question | Among ambulatory specialty practices managing patients with global practice guidelines for gastric cancer, how does structured clinical pathway integration of tackling similarities and differences compare with usual guideline dissemination without multifaceted implementation strategy for achieving equitable overall sur... | In patients with global practice guidelines for gastric cancer, how does tackling similarities compare with usual guideline dissemination without multifaceted implementation strategy regarding overall survival and progression-free or disease-free survival over 48 months? | Among individuals with global practice guidelines for gastric cancer (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does tackling similarities offer meaningful long-term benefits over usual guideline dissemination without multifaceted implementation strategy across 48 months? | In oncology and hematology, managing global practice guidelines for gastric cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of tackling similarities and difference... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Global practice guidelines for gastric cancer | Patients with global practice guidelines for gastric cancer | implementation | Tackling similarities | Usual guideline dissemination without multifaceted implementation strategy | 48 months | implementation | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Yen CC et al., Sun Q et al., Lu Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1007/s10120-026-01753-8 | Yen CC et al., Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026); DOI: 10.1007/s10120-026-01753-8 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000009 | 9 | Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome — Open Prevention Question | Across community and clinical cohorts of adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, does sustained preventive intervention with delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endo... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does delphi panel consensus on recommendations compare with routine risk-factor modification or standard surveillance without targeted prophylaxis regarding recurrent venous th... | What are the real-world benefits and risks of delphi panel consensus on recommendations versus routine risk-factor modification or standard surveillance without targeted prophylaxis over 24 months for patients managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | prevention | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Delphi panel consensus on recommendations | Routine risk-factor modification or standard surveillance without targeted prophylaxis | 24 months | population_health | multiple_small_studies | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Isand K et al., Li HY et al., Hashem M et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.1093/ejendo/lvaf017 | Isand K et al., European journal of endocrinology (2025); DOI: 10.1093/ejendo/lvaf017 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000010 | 10 | Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma — Open Supportive Palliative Question | For patients with head and neck squamous cell carcinoma experiencing symptom burden, does integrated supportive or palliative care via combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors improve EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden and overall survival... | In patients with head and neck squamous cell carcinoma, how does combination of Anti-EGFR monoclonal antibodies compare with usual symptom-directed care without integrated supportive pathway regarding overall survival and progression-free or disease-free survival over 18 months? | For people with head and neck squamous cell carcinoma, how does combination of Anti-EGFR monoclonal antibodies compare with usual symptom-directed care without integrated supportive pathway for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immune... | In oncology and hematology, managing head and neck squamous cell carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of expert consensus on the combination of Anti-... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Head and neck squamous cell carcinoma | Patients with head and neck squamous cell carcinoma | PICOTS | Combination of Anti-EGFR monoclonal antibodies | Usual symptom-directed care without integrated supportive pathway | 18 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Xue L et al., Srinivasmurthy R et al., Inoue T et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,025 | https://doi.org/10.1016/j.ctrv.2025.103048 | Xue L et al., Cancer treatment reviews (2025); DOI: 10.1016/j.ctrv.2025.103048 | NCT07110662 (PHASE1/PHASE2, NOT_YET_RECRUITING): New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibod (SRC-MED-NCT-0049) | 3 | 5 | true |
UMED-000011 | 11 | Accuracy of large language models in interpreting urological clinical guidelines — Open Diagnosis Question | Among patients with interpreting urological clinical guidelines, does integrating accuracy of large language models into the diagnostic pathway outperform conventional clinicopathologic, imaging, or laboratory reference standard in sensitivity, specificity, and downstream overall survival and progression-free or diseas... | In patients with interpreting urological clinical guidelines, how does large language models compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-free survival over 24 months? | In patients affected by interpreting urological clinical guidelines, what is the clearest medical evidence on whether large language models works better than conventional clinicopathologic, imaging, or laboratory reference standard over 24 months? | In oncology and hematology, managing interpreting urological clinical guidelines (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of accuracy of large language models in i... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Interpreting urological clinical guidelines | Patients with interpreting urological clinical guidelines | PIRD | Large language models | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Borque-Fernando Á et al., Yu H et al., Thieblemont C et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1177/17562872261436905 | Borque-Fernando Á et al., Therapeutic advances in urology (2026); DOI: 10.1177/17562872261436905 | NCT01410630 (OBSERVATIONAL, COMPLETED): FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma (SRC-MED-NCT-0019) | 3 | 5 | true |
UMED-000012 | 12 | Immune Checkpoint Inhibitor-Associated Acute Kidney Injury — Open Health Services Question | Among patients evaluated for immune checkpoint Inhibitor-Associated acute kidney injury in oncology and hematology (especially high-risk clinical subgroups, underrepresented age and comorbidity strata), what is the cost-effectiveness, capacity impact, and clinical effect on overall survival and progression-free or dise... | In patients evaluated for immune checkpoint Inhibitor-Associated acute kidney injury in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in immune checkpoint Inhibitor-Associated acute kidney injury compare with conventional specialty or hospital-centered care delive... | Can guideline-directed clinical management and biomarker stratification in immune checkpoint Inhibitor-Associated acute kidney injury safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 m... | In oncology and hematology, managing immune checkpoint Inhibitor-Associated acute kidney injury (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of immune checkpoint Inhib... | health_services | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Immune Checkpoint Inhibitor-Associated Acute Kidney Injury | Patients evaluated for immune checkpoint Inhibitor-Associated acute kidney injury in oncology and hematology | health_systems | Guideline-directed clinical management and biomarker stratification in immune checkpoint Inhibitor-Associated acute kidney injury | Conventional specialty or hospital-centered care delivery model | 18 months | health_system | observational_only | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Gupta S et al., Zhang N et al., Qiao T et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1681/asn.0000001232 | Gupta S et al., Journal of the American Society of Nephrology : JASN (2026); DOI: 10.1681/asn.0000001232 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000013 | 13 | Local management of second ipsilateral breast cancer events after primary breast-conserving therapy — Open Public Health Question | For public health programs serving adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, does community-wide deployment of local management of second ipsilateral breast cancer events after primary breast-conserving therapy achieve sustainable improvements i... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does local management of second ipsilateral breast cancer events compare with status-quo population health policy without targeted equity intervention regarding overall survival and progression-fr... | Among individuals with early-stage hormone-receptor-positive HER2-negative breast cancer (including premenopausal women, patients >=70 years with frailty), does local management of second ipsilateral breast cancer events offer meaningful long-term benefits over status-quo population health policy without targeted equit... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of local manage... | public_health | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | health_systems | Local management of second ipsilateral breast cancer events | Status-quo population health policy without targeted equity intervention | 60 months | population_health | observational_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Hannoun-Levi JM et al., Bae SJ et al., Yao S et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1016/s1470-2045(26)00177-4 | Hannoun-Levi JM et al., The Lancet. Oncology (2026); DOI: 10.1016/s1470-2045(26)00177-4 | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000014 | 14 | Management of venous thromboembolism in stroke — Open Implementation Question | In scaling evidence-based care for adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, does audit-feedback and decision support for venous thromboembolism in stroke close care gaps across thrombocytopenia 25-50 x10^9/L, hepatic or rena... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months compare with continued full-dose DOAC or weight-adjusted daltep... | What are the real-world benefits and risks of reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months versus continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin over 24 months for patients managing cancer-associated venous thromboembolism in active gastr... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | implementation | Reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months | Continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin | 24 months | implementation | multiple_small_studies | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Li HY et al., Isand K et al., Prandoni P et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.1016/j.thromres.2025.109515 | Li HY et al., Thrombosis research (2025); DOI: 10.1016/j.thromres.2025.109515 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000015 | 15 | Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer — Open Diagnosis Question | In patients with head and neck cancer presenting for clinical evaluation, what is the diagnostic accuracy and clinical utility of defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions compared with conventional clinicopathologic, imaging, or laboratory reference standard for im... | In patients with head and neck cancer, how does defining physician acceptance of radiosensitivity testing compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-free survival over 24 months? | For people with head and neck cancer, how does defining physician acceptance of radiosensitivity testing compare with conventional clinicopathologic, imaging, or laboratory reference standard for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immu... | In oncology and hematology, managing head and neck cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of defining physician acceptance of radiosensitivity testing for... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Head and neck cancer | Patients with head and neck cancer | PIRD | Defining physician acceptance of radiosensitivity testing | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Thariat J et al., Petit C et al., Tomizawa K et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.ctro.2026.101208 | Thariat J et al., Clinical and translational radiation oncology (2026); DOI: 10.1016/j.ctro.2026.101208 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000016 | 16 | Defining the Role of SABR in Head and Neck Cancer — Open Measurement Question | Among patients with head and neck cancer, is defining the role of SABR a validated surrogate or core outcome measure capable of reliably predicting overall survival and progression-free or disease-free survival over 24 months compared with legacy clinician-rated or unharmonized outcome assessment instrument? | In patients with head and neck cancer, how does defining the role of SABR compare with legacy clinician-rated or unharmonized outcome assessment instrument regarding overall survival and progression-free or disease-free survival over 24 months? | In patients affected by head and neck cancer, what is the clearest medical evidence on whether defining the role of SABR works better than legacy clinician-rated or unharmonized outcome assessment instrument over 24 months? | In oncology and hematology, managing head and neck cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of defining the role of SABR in head and neck cancer (Petit C et... | measurement | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Head and Neck Cancer | Patients with head and neck cancer | PIRD | Defining the Role of SABR | Legacy clinician-rated or unharmonized outcome assessment instrument | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Petit C et al., Thariat J et al., Lee JH et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.ijrobp.2026.05.019 | Petit C et al., International journal of radiation oncology, biology, physics (2026); DOI: 10.1016/j.ijrobp.2026.05.019 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000017 | 17 | Real-World Achievement of Guideline-Concordant Treatment and Survival in Osteosarcoma — Open Prognosis Question | Across independent cohorts of patients with osteosarcoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), how reliably does Real-World achievement of Guideline-Concordant treatment and survival predict long-term overall survival and progression-free or disease-free survival and Gra... | In patients with osteosarcoma, how does Real-World achievement of Guideline-Concordant treatment compare with standard clinical risk score without Real-World achievement of Guideline-Concordant treatment stratification regarding overall survival and progression-free or disease-free survival over 24 months? | Can Real-World achievement of Guideline-Concordant treatment safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 24 months compared with standard clinical risk score without Real-World achie... | In oncology and hematology, managing osteosarcoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Real-World achievement of Guideline-Concordant treatment and survival... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Osteosarcoma | Patients with osteosarcoma | prognostic | Real-World Achievement of Guideline-Concordant Treatment | Standard clinical risk score without Real-World achievement of Guideline-Concordant treatment stratification | 24 months | early_clinical | observational_only | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Fujiwara T et al., Otto SD et al., Suprasert P et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1111/cas.70525 | Fujiwara T et al., Cancer science (2026); DOI: 10.1111/cas.70525 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000018 | 18 | Risk-adapted neck dissection in salivary gland carcinoma — Open Implementation Question | Among ambulatory specialty, laboratory or pathology practices managing patients with salivary gland carcinoma, how does structured clinical pathway integration of risk-adapted neck dissection compare with usual guideline dissemination without multifaceted implementation strategy for achieving equitable overall survival... | In patients with salivary gland carcinoma, how does risk-adapted neck dissection compare with usual guideline dissemination without multifaceted implementation strategy regarding overall survival and progression-free or disease-free survival over 24 months? | Among individuals with salivary gland carcinoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does risk-adapted neck dissection offer meaningful long-term benefits over usual guideline dissemination without multifaceted implementation strategy across 24 months? | In oncology and hematology, managing salivary gland carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of risk-adapted neck dissection in salivary gland carcinoma ... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Salivary gland carcinoma | Patients with salivary gland carcinoma | implementation | Risk-adapted neck dissection | Usual guideline dissemination without multifaceted implementation strategy | 24 months | implementation | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Johnson F et al., Song Y et al., Zhang H et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.3389/fonc.2026.1916521 | Johnson F et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1916521 | NCT01490723 (PHASE2, COMPLETED): Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) (SRC-MED-NCT-0020) | 3 | 5 | true |
UMED-000019 | 19 | SEOM-GEICO clinical guidelines on endometrial cancer (2025) — Open Implementation Question | In scaling evidence-based care for patients evaluated for SEOM-GEICO clinical guidelines on endometrial cancer (2025) in oncology and hematology, does audit-feedback and decision support for guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025... | In patients evaluated for SEOM-GEICO clinical guidelines on endometrial cancer (2025) in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025) compare with usual guideline dissemination without multifaceted im... | What are the real-world benefits and risks of guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025) versus usual guideline dissemination without multifaceted implementation strategy over 24 months for patients managing SEOM-GEICO clinical guid... | In oncology and hematology, managing SEOM-GEICO clinical guidelines on endometrial cancer (2025) (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of SEOM-GEICO clinical gu... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | SEOM-GEICO clinical guidelines on endometrial cancer (2025) | Patients evaluated for SEOM-GEICO clinical guidelines on endometrial cancer (2025) in oncology and hematology | implementation | Guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025) | Usual guideline dissemination without multifaceted implementation strategy | 24 months | implementation | multiple_small_studies | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Ramírez SP et al., Junling L et al., Wang ZH et al. & World Health Organization (WHO) Global Research Agenda | 2,025 | https://doi.org/10.1007/s12094-025-04046-1 | Ramírez SP et al., Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2025); DOI: 10.1007/s12094-025-04046-1 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000020 | 20 | International Dermoscopy Society consensus recommendations for the management of lentigo maligna — Open Etiology Question | In patients with lentigo maligna, what is the causal contribution of international dermoscopy society consensus recommendations for the management of lentigo maligna—and its interaction with host susceptibility—to disease development and overall survival and progression-free or disease-free survival over 36 months comp... | In patients with lentigo maligna, how does international dermoscopy society consensus recommendations compare with unexposed or baseline reference risk cohort in lentigo maligna regarding overall survival and progression-free or disease-free survival over 36 months? | For people with lentigo maligna, how does international dermoscopy society consensus recommendations compare with unexposed or baseline reference risk cohort in lentigo maligna for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immune-mediated adv... | In oncology and hematology, managing lentigo maligna (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of international dermoscopy society consensus recommendations for the... | etiology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Lentigo maligna | Patients with lentigo maligna | PECO | International Dermoscopy Society consensus recommendations | Unexposed or baseline reference risk cohort in lentigo maligna | 36 months | fundamental_human_mechanism | observational_only | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Forsea AM et al., Ru Y et al., Ito K et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1111/jdv.70406 | Forsea AM et al., Journal of the European Academy of Dermatology and Venereology : JEADV (2026); DOI: 10.1111/jdv.70406 | NCT02789254 (PHASE1/PHASE2, COMPLETED): FLYSYN in MRD Positive AML (SRC-MED-NCT-0010) | 3 | 5 | true |
UMED-000021 | 21 | Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer — Open Safety Question | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade (especially patients with treated brain metastases, autoimmune comorbidity), what patient-level risk factors and monitoring thresholds predict severe Grade >=3 treatment-related and immune-mediated ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does efficacy compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 48 months? | In patients affected by metastatic non-small cell lung cancer without targetable driver mutations, what is the clearest medical evidence on whether efficacy works better than alternative active comparator or standard dose-monitoring regimen over 48 months? | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safe... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Efficacy | Alternative active comparator or standard dose-monitoring regimen | 48 months | post_authorization | one_pivotal_study | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Han H et al., Zhao Y et al., Mahato S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1820515 | Han H et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1820515 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000022 | 22 | Nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy in pMMR/MSS locally advanced rectal cancer — Open Treatment Strategy Question | Among adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy, when can therapy be safely de-escalated, switched, or intensified using nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy compared with mandatory radical total mes... | In adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy, how does organ-preserving watch-and-wait surveillance after clinical complete response to total neoadjuvant therapy compare with mandatory radical total mesorectal excision regardless of clinical response regarding... | Can organ-preserving watch-and-wait surveillance after clinical complete response to total neoadjuvant therapy safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with man... | In oncology and hematology, managing locally advanced mismatch-repair-proficient rectal adenocarcinoma (clinical stage T3-T4 or node-positive) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of nonlinear durati... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Locally advanced mismatch-repair-proficient rectal adenocarcinoma | Adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy | PICOTS | Organ-preserving watch-and-wait surveillance after clinical complete response to total neoadjuvant therapy | Mandatory radical total mesorectal excision regardless of clinical response | 60 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 2 | moderate | open | OPEN-VERIFIED | Hu S et al., Eltahir AA et al., Sileika E et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.3389/fonc.2026.1855615 | Hu S et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1855615 | NCT07580339 (PHASE2, NOT_YET_RECRUITING): Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Adva (SRC-MED-NCT-0015) | 3 | 5 | true |
UMED-000023 | 23 | Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer — Open Prognosis Question | For adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, can baseline and serial assessment of PIK3CA mutations for response to CDK4/6 inhibitors accurately stratify individual risk of overall survival and progression-free or disease-free survival over 60 ... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does PIK3CA mutations compare with standard clinical risk score without PIK3CA mutations stratification regarding overall survival and progression-free or disease-free survival over 60 months? | Among individuals with early-stage hormone-receptor-positive HER2-negative breast cancer (including premenopausal women, patients >=70 years with frailty), does PIK3CA mutations offer meaningful long-term benefits over standard clinical risk score without PIK3CA mutations stratification across 60 months? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of predictive value of PIK3C... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | prognostic | PIK3CA Mutations | Standard clinical risk score without PIK3CA mutations stratification | 60 months | early_clinical | observational_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Qureshi Z et al., Zhang M et al., Veta Darkovski J et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1097/coc.0000000000001294 | Qureshi Z et al., American journal of clinical oncology (2026); DOI: 10.1097/coc.0000000000001294 | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000024 | 24 | Reduced Versus Full-Dose Direct Oral Anticoagulants for Venous Thromboembolism in Cancer Patients — Open Methodology Question | When validating predictive or causal claims regarding reduced versus Full-Dose direct oral anticoagulants for venous thromboembolism in adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, what external transportability and bias-quantif... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced direct oral anticoagulants compare with Full-Dose direct oral anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over 24 mo... | What are the real-world benefits and risks of reduced direct oral anticoagulants versus Full-Dose direct oral anticoagulants over 24 months for patients managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Reduced Direct Oral Anticoagulants | Full-Dose Direct Oral Anticoagulants | 24 months | confirmatory_clinical | systematic_review_low_certainty | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Bakht D et al., Akhtar M et al., Joshi DK et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.1002/jha2.70155 | Bakht D et al., EJHaem (2025); DOI: 10.1002/jha2.70155 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000025 | 25 | Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism — Open Methodology Question | In clinical studies of adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation addressing Reduced-Dose versus Full-Dose direct oral anticoagulants, which study design and causal-inference framework best resolves confounding, time-zero bias,... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does Reduced-Dose direct oral anticoagulants compare with Full-Dose direct oral anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over ... | For people with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy, how does Reduced-Dose direct oral anticoagulants compare with Full-Dose direct oral anticoagulants for improving recurrent venous thromboembolism and clinically relevant bleeding and minimizing ISTH major bl... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Reduced-Dose Direct Oral Anticoagulants | Full-Dose Direct Oral Anticoagulants | 24 months | confirmatory_clinical | systematic_review_low_certainty | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Akhtar M et al., Bakht D et al., Bacha Z et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1007/s10557-025-07759-1 | Akhtar M et al., Cardiovascular drugs and therapy (2026); DOI: 10.1007/s10557-025-07759-1 | NCT07270263 (NA, RECRUITING): Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hema (SRC-MED-NCT-0025) | 3 | 5 | true |
UMED-000026 | 26 | Immune-related adverse events with cancer clinical benefits — Open Safety Question | In patients evaluated for immune-related adverse events with cancer clinical benefits in oncology and hematology (especially high-risk clinical subgroups, underrepresented age and comorbidity strata), what patient-level risk factors and monitoring thresholds predict severe Grade >=3 treatment-related and immune-mediate... | In patients evaluated for immune-related adverse events with cancer clinical benefits in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in immune-related adverse events with cancer clinical benefits compare with alternative active comparator or standard dose-monito... | In patients affected by immune-related adverse events with cancer clinical benefits, what is the clearest medical evidence on whether guideline-directed clinical management and biomarker stratification in immune-related adverse events with cancer clinical benefits works better than alternative active comparator or stan... | In oncology and hematology, managing immune-related adverse events with cancer clinical benefits (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of immune-related adverse... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Immune-related adverse events with cancer clinical benefits | Patients evaluated for immune-related adverse events with cancer clinical benefits in oncology and hematology | PICOTS | Guideline-directed clinical management and biomarker stratification in immune-related adverse events with cancer clinical benefits | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Li Z et al., Chen B et al., Zhu J et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12885-026-16446-9 | Li Z et al., BMC cancer (2026); DOI: 10.1186/s12885-026-16446-9 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000027 | 27 | Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Anticoagulation Therapy in Patients With Venous Thromboembolism — Open Methodology Question | In synthesizing heterogeneous evidence on Reduced-Dose vs Full-Dose direct oral anticoagulants for extended anticoagulation therapy in adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, can individual participant data meta-analysis or... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does Reduced-Dose direct oral anticoagulants compare with Full-Dose direct oral anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over ... | Can Reduced-Dose direct oral anticoagulants safely improve recurrent venous thromboembolism and clinically relevant bleeding and quality of life (anticoagulation treatment burden and health-related quality of life) over 24 months compared with Full-Dose direct oral anticoagulants for people with cancer-associated venou... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Reduced-Dose Direct Oral Anticoagulants | Full-Dose Direct Oral Anticoagulants | 24 months | confirmatory_clinical | systematic_review_low_certainty | specialist_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Joshi DK et al., Bakry HE et al., Bitonti TM et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1016/j.jscai.2026.105317 | Joshi DK et al., Journal of the Society for Cardiovascular Angiography & Interventions (2026); DOI: 10.1016/j.jscai.2026.105317 | NCT07270263 (NA, RECRUITING): Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hema (SRC-MED-NCT-0025) | 3 | 5 | true |
UMED-000028 | 28 | CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients — Open Natural History Question | In unselected prospective follow-up of adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, what factors modify longitudinal progression to overall survival and progression-free or disease-free survival over 60 months under CDK4/6 inhibitors rechallenge po... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does CDK4/6 inhibitors rechallenge post-progression compare with standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2-negative breast cancer regarding o... | Among individuals with early-stage hormone-receptor-positive HER2-negative breast cancer (including premenopausal women, patients >=70 years with frailty), does CDK4/6 inhibitors rechallenge post-progression offer meaningful long-term benefits over standard longitudinal clinical surveillance cohort in early-stage hormo... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of CDK4/6 inhibitors rechall... | natural_history | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | natural_history | CDK4/6 inhibitors rechallenge post-progression | Standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2-negative breast cancer | 60 months | early_clinical | observational_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Veta Darkovski J et al., Birsin Z et al., Ye M et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1186/s13058-026-02311-x | Veta Darkovski J et al., Breast cancer research : BCR (2026); DOI: 10.1186/s13058-026-02311-x | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000029 | 29 | Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC — Open Treatment Strategy Question | In patients with advanced or metastatic NSCLC, does dynamic treatment adaptation guided by PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs improve overall survival and progression-free or disease-free survival over 48 months compared with standard fixed-duration or unselected dosing regimen in a... | In patients with advanced or metastatic NSCLC, how does PD-1/PD-L1 inhibitors combined compare with standard fixed-duration or unselected dosing regimen in advanced or metastatic NSCLC regarding overall survival and progression-free or disease-free survival over 48 months? | What are the real-world benefits and risks of PD-1/PD-L1 inhibitors combined versus standard fixed-duration or unselected dosing regimen in advanced or metastatic NSCLC over 48 months for patients managing advanced or metastatic NSCLC? | In oncology and hematology, managing advanced or metastatic NSCLC (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced or metastatic NSCLC | Patients with advanced or metastatic NSCLC | PICOTS | PD-1/PD-L1 inhibitors combined | Standard fixed-duration or unselected dosing regimen in advanced or metastatic NSCLC | 48 months | comparative_effectiveness | multiple_small_studies | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Tang Z et al., Kong Y et al., Han H et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1799126 | Tang Z et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1799126 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000030 | 30 | First-line therapies with maintenance regimens for driver gene-negative advanced non-small cell lung cancer (NSCLC) — Open Treatment Strategy Question | For adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade in ambulatory specialty settings, what is the optimal sequencing, dosing threshold, or treatment duration of first-line therapies with maintenance regimens for driver gene-negative advanced non-sma... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does first-line therapies with maintenance regimens compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutation... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does first-line therapies with maintenance regimens compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations for improving overall survival... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of first-line therapies wit... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | First-line therapies with maintenance regimens | Standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | comparative_effectiveness | multiple_small_studies | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Zhao Y et al., Peruzzo N et al., Wang Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.21037/jtd-2025-aw-2087 | Zhao Y et al., Journal of thoracic disease (2026); DOI: 10.21037/jtd-2025-aw-2087 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000031 | 31 | The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer — Open Natural History Question | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does the long-term clinical course of overall survival and progression-free or disease-free survival evolve over 24 months when stratified by PARP inhibitor-based targeted therapy on BRCA-muta... | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does PARP inhibitor-based targeted therapy compare with standard longitudinal clinical surveillance cohort in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovari... | In patients affected by BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer, what is the clearest medical evidence on whether PARP inhibitor-based targeted therapy works better than standard longitudinal clinical surveillance cohort in BRCA-wildtype homologous-recombination-profi... | In oncology and hematology, managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer (FIGO stage III-IV post-platinum) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | natural_history | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | BRCA-wildtype homologous-recombination-proficient advanced high-grade serous ovarian cancer | Women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy | natural_history | PARP inhibitor-based targeted therapy | Standard longitudinal clinical surveillance cohort in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer | 24 months | early_clinical | observational_only | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Panjarwanto DA et al., Feng J et al., Salutari V et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1778168 | Panjarwanto DA et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1778168 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000032 | 32 | Treatment outcomes for patients with newly diagnosed or relapsed/refractory TP53-mutated mantle cell lymphoma — Open Screening Question | For risk-stratified adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma, does longitudinal surveillance using treatment outcomes reduce late-stage presentation and improve overall survival and progression-free or disease-free survival over 36 months compared... | In adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma, how does treatment outcomes compare with symptom-prompted clinical evaluation or current guideline screening schedule regarding overall survival and progression-free or disease-free survival over 36 mon... | Can treatment outcomes safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 36 months compared with symptom-prompted clinical evaluation or current guideline screening schedule for people wit... | In oncology and hematology, managing relapsed or refractory follicular and mantle cell lymphoma (relapsed or refractory stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of treatment outcomes for patients ... | screening | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Relapsed or refractory follicular and mantle cell lymphoma | Adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma | PIRD | Treatment outcomes | Symptom-prompted clinical evaluation or current guideline screening schedule | 36 months | population_health | observational_only | specialist_consensus_open | 3 | hard | open | OPEN-VERIFIED | Zhang N et al., Castillo DR et al., Fonseca JM et al. & Cochrane Collaboration Evidence Synthesis Group | 2,025 | https://doi.org/10.1016/j.eclinm.2025.103336 | Zhang N et al., EClinicalMedicine (2025); DOI: 10.1016/j.eclinm.2025.103336 | NCT00293345 (PHASE1, COMPLETED): 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (SRC-MED-NCT-0047) | 3 | 5 | true |
UMED-000033 | 33 | Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer — Open Treatment Strategy Question | What is the optimal clinical algorithm for initiating and sequencing Anti-PD-(l)1 plus chemotherapy relative to standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations to maximize overall survival and progression-free or disease-free survival ove... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does Anti-PD-(l)1 plus chemotherapy compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations regarding over... | Among individuals with metastatic non-small cell lung cancer without targetable driver mutations (including patients with treated brain metastases, autoimmune comorbidity), does Anti-PD-(l)1 plus chemotherapy offer meaningful long-term benefits over standard fixed-duration or unselected dosing regimen in metastatic non... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Anti-PD-(l)1 plus chemot... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Anti-PD-(L)1 plus chemotherapy | Standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Peruzzo N et al., Qin X et al., Song Q et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1080/1750743x.2026.2689298 | Peruzzo N et al., Immunotherapy (2026); DOI: 10.1080/1750743x.2026.2689298 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000034 | 34 | CAR-T Versus Non-CAR-T Bridging Strategies Before Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia — Open Rehabilitation Question | Across heterogeneous recovery profiles in patients with Relapsed/Refractory B-Cell acute lymphoblastic leukemia, which subgroups derive clinically meaningful functional benefit from CAR-T versus Non-CAR-T bridging strategies before allogeneic hematopoietic stem cell transplantation over 36 months compared with usual ph... | In patients with Relapsed/Refractory B-Cell acute lymphoblastic leukemia, how does CAR-T versus Non-CAR-T bridging strategies before allogeneic hematopoietic stem cell compare with usual physical and functional care without structured rehabilitation pathway regarding overall survival and progression-free or disease-fre... | What are the real-world benefits and risks of CAR-T versus Non-CAR-T bridging strategies before allogeneic hematopoietic stem cell versus usual physical and functional care without structured rehabilitation pathway over 36 months for patients managing Relapsed/Refractory B-Cell acute lymphoblastic leukemia? | In oncology and hematology, managing Relapsed/Refractory B-Cell acute lymphoblastic leukemia (relapsed or refractory stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of CAR-T versus Non-CAR-T bridging str... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Patients with Relapsed/Refractory B-Cell acute lymphoblastic leukemia | PICOTS | CAR-T Versus Non-CAR-T Bridging Strategies Before Allogeneic Hematopoietic Stem Cell | Usual physical and functional care without structured rehabilitation pathway | 36 months | comparative_effectiveness | multiple_small_studies | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Halloumi O et al., Dong R et al., Abdelmagid M et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.7759/cureus.115393 | Halloumi O et al., Cureus (2026); DOI: 10.7759/cureus.115393 | NCT01347996 (PHASE4, COMPLETED): Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myel (SRC-MED-NCT-0011) | 3 | 5 | true |
UMED-000035 | 35 | Circulating Tumor DNA is Associated With Pathologic Response and Survival Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy — Open Prognosis Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, what is the externally validated prognostic discrimination, calibration, and decision utility of circulating tumor DNA is associated with pathologic response and survival outcomes versus standar... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does circulating tumor DNA is associated with pathologic response compare with standard clinical risk score without circulating tumor DNA is associated with pathologic response stratification r... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does circulating tumor DNA is associated with pathologic response compare with standard clinical risk score without circulating tumor DNA is associated with pathologic response stratification for improving overall survival an... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of circulating tumor DNA is... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | prognostic | Circulating Tumor DNA is Associated With Pathologic Response | Standard clinical risk score without circulating tumor DNA is associated with pathologic response stratification | 48 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Song Q et al., Chen Z et al., Kakouri AC et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.arbres.2026.05.021 | Song Q et al., Archivos de bronconeumologia (2026); DOI: 10.1016/j.arbres.2026.05.021 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000036 | 36 | FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia — Open Supportive Palliative Question | In adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, what is the comparative effectiveness of early, structured FLAG-Based versus standard 7+3 induction therapy versus standard 7+3 induction therapy for relieving refractory symptom... | In adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, how does FLAG-Based 7+3 induction therapy compare with standard 7+3 induction therapy regarding overall survival and progression-free or disease-free survival over 36 months? | In patients affected by acute myeloid leukemia in first complete remission, what is the clearest medical evidence on whether FLAG-Based 7+3 induction therapy works better than standard 7+3 induction therapy over 36 months? | In oncology and hematology, managing acute myeloid leukemia in first complete remission (first complete remission (CR1)) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of FLAG-Based versus standard 7+3 inducti... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Acute myeloid leukemia in first complete remission | Adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine | PICOTS | FLAG-Based 7+3 Induction Therapy | Standard 7+3 Induction Therapy | 36 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 5 | frontier | open | OPEN-VERIFIED | Abdulgayoom M et al., Chang YS et al., Fathima S et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1159/000552987 | Abdulgayoom M et al., Oncology (2026); DOI: 10.1159/000552987 | NCT01347996 (PHASE4, COMPLETED): Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myel (SRC-MED-NCT-0011) | 3 | 5 | true |
UMED-000037 | 37 | Fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma — Open Safety Question | For patients with metastatic urothelial carcinoma receiving treatment in inpatient ward, ambulatory specialty settings, how does the long-term safety and pharmacovigilance profile of fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition compare with alternative active comp... | In patients with metastatic urothelial carcinoma, how does fibroblast growth factor receptor 3 (FGFR3) alterations compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 18 months? | Can fibroblast growth factor receptor 3 (FGFR3) alterations safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 months compared with alternative active comparator or standard dose-monitor... | In oncology and hematology, managing metastatic urothelial carcinoma (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of fibroblast growth factor receptor 3 (FGFR3) alterations and... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic urothelial carcinoma | Patients with metastatic urothelial carcinoma | PICOTS | Fibroblast growth factor receptor 3 (FGFR3) alterations | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Oey O et al., Ma Q et al., Trovato G et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1007/s12094-026-04560-w | Oey O et al., Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2026); DOI: 10.1007/s12094-026-04560-w | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000038 | 38 | Optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer — Open Treatment Strategy Question | What is the optimal clinical algorithm for initiating and sequencing optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy relative to standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations to maximize overall survival ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does optimal duration of adjuvant immunotherapy compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations re... | Among individuals with metastatic non-small cell lung cancer without targetable driver mutations (including patients with treated brain metastases, autoimmune comorbidity), does optimal duration of adjuvant immunotherapy offer meaningful long-term benefits over standard fixed-duration or unselected dosing regimen in me... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of optimal duration of adju... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Optimal duration of adjuvant immunotherapy | Standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Chen Z et al., Osarogiagbon RU et al., Wang S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.21037/jtd-2025-1389 | Chen Z et al., Journal of thoracic disease (2026); DOI: 10.21037/jtd-2025-1389 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000039 | 39 | Reassessing the Role of Anthracyclines in Early HER2-Positive Breast Cancer in the Era of HER2-Targeted Therapy and Treatment De-Escalation — Open Treatment Strategy Question | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, does dynamic treatment adaptation guided by anthracyclines improve overall survival and progression-free or disease-free survival over 60 months compared with standard fixed-duration or unselected dos... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does anthracyclines compare with standard fixed-duration or unselected dosing regimen in early-stage hormone-receptor-positive HER2-negative breast cancer regarding overall survival and progressio... | What are the real-world benefits and risks of anthracyclines versus standard fixed-duration or unselected dosing regimen in early-stage hormone-receptor-positive HER2-negative breast cancer over 60 months for patients managing early-stage hormone-receptor-positive HER2-negative breast cancer? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of reassessing ... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | PICOTS | Anthracyclines | Standard fixed-duration or unselected dosing regimen in early-stage hormone-receptor-positive HER2-negative breast cancer | 60 months | comparative_effectiveness | multiple_small_studies | active_scientific_dispute | 5 | frontier | contested | DISPUTED-OPEN | Myrzabay Z et al., Li X et al., Kakimoto S et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.3390/jcm15187303 | Myrzabay Z et al., Journal of clinical medicine (2026); DOI: 10.3390/jcm15187303 | NCT06781281 (OBSERVATIONAL, RECRUITING): NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. (SRC-MED-NCT-0001) | 3 | 5 | true |
UMED-000040 | 40 | The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy — Open Prognosis Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, what is the externally validated prognostic discrimination, calibration, and decision utility of the predictive role of CTDNA and CTCs versus standard clinical risk score without the predictive ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does the predictive role of CTDNA and CTCs compare with standard clinical risk score without the predictive role of CTDNA and CTCs stratification regarding overall survival and progression-free... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does the predictive role of CTDNA and CTCs compare with standard clinical risk score without the predictive role of CTDNA and CTCs stratification for improving overall survival and progression-free or disease-free survival an... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of the predictive role of C... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | prognostic | The Predictive Role of ctDNA and CTCs | Standard clinical risk score without the predictive role of CTDNA and CTCs stratification | 48 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Kakouri AC et al., Lu D et al., Li Z et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3390/ijms27125518 | Kakouri AC et al., International journal of molecular sciences (2026); DOI: 10.3390/ijms27125518 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000041 | 41 | Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Cancer — Open Comparative Effectiveness Question | Among adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, what is the head-to-head comparative effectiveness of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for borderline resectable pancreatic cancer versus standard neoadjuva... | In adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, how does total neoadjuvant therapy compare with standard neoadjuvant chemoradiotherapy regarding overall survival and progression-free or disease-free survival over 36 months? | In patients affected by borderline resectable and locally advanced pancreatic ductal adenocarcinoma, what is the clearest medical evidence on whether total neoadjuvant therapy works better than standard neoadjuvant chemoradiotherapy over 36 months? | In oncology and hematology, managing borderline resectable and locally advanced pancreatic ductal adenocarcinoma (NCCN borderline resectable or locally advanced) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies ... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Borderline resectable and locally advanced pancreatic ductal adenocarcinoma | Adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy | PICOTS | Total Neoadjuvant Therapy | Standard Neoadjuvant Chemoradiotherapy | 36 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Gupta S et al., Zuo H et al., Yeung KTD et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.7759/cureus.115551 | Gupta S et al., Cureus (2026); DOI: 10.7759/cureus.115551 | NCT06944587 (OBSERVATIONAL, RECRUITING): A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advance (SRC-MED-NCT-0043) | 3 | 5 | true |
UMED-000042 | 42 | A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer — Open Safety Question | For patients with colorectal cancer receiving treatment in inpatient ward, ambulatory specialty settings, how does the long-term safety and pharmacovigilance profile of a network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors compare with alternative active comparator or standard dose... | In patients with colorectal cancer, how does a network meta-analysis of endocrine adverse events induced by immune checkpoint compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 18 months? | Can a network meta-analysis of endocrine adverse events induced by immune checkpoint safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 months compared with alternative active comparator... | In oncology and hematology, managing colorectal cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of a network meta-analysis of endocrine adverse events induced by i... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Colorectal cancer | Patients with colorectal cancer | PICOTS | A network meta-analysis of endocrine adverse events induced by immune checkpoint | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Chen B et al., Li Z et al., Wang Y et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.3389/fimmu.2026.1798732 | Chen B et al., Frontiers in immunology (2026); DOI: 10.3389/fimmu.2026.1798732 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000043 | 43 | Aspirin Versus Other Anticoagulants for the Initial Prevention of Venous Thromboembolism Following Elective Total Hip and Knee Arthroplasty — Open Prevention Question | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, what is the optimal timing and risk threshold for initiating preventive aspirin versus other anticoagulants for the initial prevention of venous thromboembolism following elective ... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does aspirin anticoagulants compare with other anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over 24 months? | Among individuals with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (including thrombocytopenia 25-50 x10^9/L, hepatic or renal dysfunction), does aspirin anticoagulants offer meaningful long-term benefits over other anticoagulants across 24 months? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | prevention | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Aspirin Anticoagulants | Other Anticoagulants | 24 months | population_health | multiple_small_studies | specialist_consensus_open | 2 | moderate | partially_resolved | PARTIAL-PROGRESS | Borazjani R et al., Gonzalez AG et al., Lan KM et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1016/j.arth.2025.06.032 | Borazjani R et al., The Journal of arthroplasty (2026); DOI: 10.1016/j.arth.2025.06.032 | NCT02285738 (EARLY_PHASE1, COMPLETED): Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis (SRC-MED-NCT-0027) | 3 | 5 | true |
UMED-000044 | 44 | Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer — Open Treatment Effectiveness Question | In randomized evaluation of adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, does comparative efficacy and safety of first, second, and third-generation eGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung canc... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does comparative efficacy and safety of first, second compare with standard-of-care therapy or active control regimen in metastatic non-small cell lung cancer without targetable driver mutation... | What are the real-world benefits and risks of comparative efficacy and safety of first, second versus standard-of-care therapy or active control regimen in metastatic non-small cell lung cancer without targetable driver mutations over 48 months for patients managing metastatic non-small cell lung cancer without targeta... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of comparative efficacy and... | treatment_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Comparative efficacy and safety of first, second | Standard-of-care therapy or active control regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | confirmatory_clinical | early_interventional | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Mahato S et al., Chen D et al., Chen S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1186/s43046-026-00414-2 | Mahato S et al., Journal of the Egyptian National Cancer Institute (2026); DOI: 10.1186/s43046-026-00414-2 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000045 | 45 | Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer — Open Safety Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade exposed to comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer versus alternative active comparator or standard dose-monitoring regimen, wha... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does comparative efficacy and safety of post-TKI treatments compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or dis... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does comparative efficacy and safety of post-TKI treatments compare with alternative active comparator or standard dose-monitoring regimen for improving overall survival and progression-free or disease-free survival and minim... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of comparative efficacy and... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Comparative efficacy and safety of post-TKI treatments | Alternative active comparator or standard dose-monitoring regimen | 48 months | post_authorization | one_pivotal_study | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Wang Y et al., Izadpanah K et al., Liu S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.lungcan.2026.108914 | Wang Y et al., Lung cancer (Amsterdam, Netherlands) (2026); DOI: 10.1016/j.lungcan.2026.108914 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000046 | 46 | Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis — Open Diagnosis Question | Among adults with solid tumors developing moderate-to-severe immune-related adverse events during PD-1/PD-L1 or CTLA-4 blockade, does integrating diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis into the diagnostic pathway outperform conventional clinicopathologic, imaging, or la... | In adults with solid tumors developing moderate-to-severe immune-related adverse events during PD-1/PD-L1 or CTLA-4 blockade, how does diagnostic and prognostic parameters compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-fr... | In patients affected by immune-related adverse events (myocarditis, pneumonitis, colitis, and endocrinopathies) from checkpoint blockade, what is the clearest medical evidence on whether diagnostic and prognostic parameters works better than conventional clinicopathologic, imaging, or laboratory reference standard over... | In oncology and hematology, managing immune-related adverse events from checkpoint blockade (CTCAE Grade 2-4 immune-related toxicity) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of diagnostic and prognostic... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Immune-related adverse events (myocarditis, pneumonitis, colitis, and endocrinopathies) from checkpoint blockade | Adults with solid tumors developing moderate-to-severe immune-related adverse events during PD-1/PD-L1 or CTLA-4 blockade | PIRD | Diagnostic and prognostic parameters | Conventional clinicopathologic, imaging, or laboratory reference standard | 18 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Lerchner T et al., Lan L et al., Zhou S et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1016/j.ejca.2026.116693 | Lerchner T et al., European journal of cancer (Oxford, England : 1990) (2026); DOI: 10.1016/j.ejca.2026.116693 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000047 | 47 | Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC) — Open Treatment Strategy Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, when can therapy be safely de-escalated, switched, or intensified using canakinumab compared with standard therapy for the treatment of Non-Small cell lung cancer (NSCLC) compared with standard ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does canakinumab therapy compare with standard therapy regarding overall survival and progression-free or disease-free survival over 48 months? | Can canakinumab therapy safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 48 months compared with standard therapy for people with metastatic non-small cell lung cancer without targetable ... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safety of c... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Canakinumab Therapy | Standard Therapy | 48 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Izadpanah K et al., Wu X et al., Guo K et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1002/cnr2.70627 | Izadpanah K et al., Cancer reports (Hoboken, N.J.) (2026); DOI: 10.1002/cnr2.70627 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000048 | 48 | Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma — Open Safety Question | What is the causal risk-benefit trade-off between gains in overall survival and progression-free or disease-free survival and cumulative Grade >=3 treatment-related and immune-mediated adverse events over 18 months when using immune-based combinations versus alternative active comparator or standard dose-monitoring reg... | In patients with metastatic hepatocellular carcinoma, how does efficacy compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 18 months? | Among individuals with metastatic hepatocellular carcinoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does efficacy offer meaningful long-term benefits over alternative active comparator or standard dose-monitoring regimen across 18 months? | In oncology and hematology, managing metastatic hepatocellular carcinoma (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safety of immune-based combinations in met... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic hepatocellular carcinoma | Patients with metastatic hepatocellular carcinoma | PICOTS | Efficacy | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | de Moura ACC et al., Duan Y et al., Wang W et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12885-026-15893-8 | de Moura ACC et al., BMC cancer (2026); DOI: 10.1186/s12885-026-15893-8 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000049 | 49 | PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups — Open Mechanism Question | In translational human studies of women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how do host-microenvironment or genetic interactions involving PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across... | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does PARP inhibitor-based first-line maintenance therapy compare with canonical baseline pathway activity or treatment-sensitive phenotype in BRCA-wildtype homologous-recombination-proficient ... | What are the real-world benefits and risks of PARP inhibitor-based first-line maintenance therapy versus canonical baseline pathway activity or treatment-sensitive phenotype in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer over 24 months for patients managing BRCA-wildtype ... | In oncology and hematology, managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer (FIGO stage III-IV post-platinum) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | mechanism | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | BRCA-wildtype homologous-recombination-proficient advanced high-grade serous ovarian cancer | Women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy | mechanistic | PARP inhibitor-based first-line maintenance therapy | Canonical baseline pathway activity or treatment-sensitive phenotype in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer | 24 months | fundamental_human_mechanism | mechanistic_evidence_only | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Feng J et al., Panjarwanto DA et al., Gąsowska-Bodnar A et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1884407 | Feng J et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1884407 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000050 | 50 | Predictive value of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer — Open Prognosis Question | Among patients with advanced/recurrent endometrial cancer, what is the externally validated prognostic discrimination, calibration, and decision utility of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy versus standard clinical risk score without PD-L1 expression and dM... | In patients with advanced/recurrent endometrial cancer, how does PD-L1 expression and dMMR/pMMR status compare with standard clinical risk score without PD-L1 expression and dMMR/pMMR status stratification regarding overall survival and progression-free or disease-free survival over 18 months? | For people with advanced/recurrent endometrial cancer, how does PD-L1 expression and dMMR/pMMR status compare with standard clinical risk score without PD-L1 expression and dMMR/pMMR status stratification for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-rel... | In oncology and hematology, managing advanced/recurrent endometrial cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of predictive value of PD-L1 expression and dMM... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced/recurrent endometrial cancer | Patients with advanced/recurrent endometrial cancer | prognostic | PD-L1 expression and dMMR/pMMR status | Standard clinical risk score without PD-L1 expression and dMMR/pMMR status stratification | 18 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Lan L et al., Aliouat A et al., Sisca L et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12957-026-04330-6 | Lan L et al., World journal of surgical oncology (2026); DOI: 10.1186/s12957-026-04330-6 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000051 | 51 | Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases — Open Patient Experience Question | In patients with non-small cell lung cancer and brain metastases (including high-risk clinical subgroups, underrepresented age and comorbidity strata), what treatment attributes, lived-experience priorities, and trade-offs between overall survival and progression-free or disease-free survival and Grade >=3 treatment-re... | In patients with non-small cell lung cancer and brain metastases, how does systemic and intracranial activity of antibody-drug conjugates compare with routine clinician-directed care without structured patient-reported decision tool regarding overall survival and progression-free or disease-free survival over 24 months... | In patients affected by non-small cell lung cancer and brain metastases, what is the clearest medical evidence on whether systemic and intracranial activity of antibody-drug conjugates works better than routine clinician-directed care without structured patient-reported decision tool over 24 months? | In oncology and hematology, managing non-small cell lung cancer and brain metastases (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of systemic and intracranial activity... | patient_experience | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Non-small cell lung cancer and brain metastases | Patients with non-small cell lung cancer and brain metastases | qualitative | Systemic and intracranial activity of antibody-drug conjugates | Routine clinician-directed care without structured patient-reported decision tool | 24 months | implementation | observational_only | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Zhou S et al., Zhang YC et al., Chen Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.lungcan.2026.109638 | Zhou S et al., Lung cancer (Amsterdam, Netherlands) (2026); DOI: 10.1016/j.lungcan.2026.109638 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000052 | 52 | Surrogate endpoints for overall survival in extensive-stage small-cell lung cancer — Open Measurement Question | Across multi-center studies of adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how can assay or instrument standardization for surrogate endpoints for overall survival eliminate inter-laboratory variability and improve overall survival and progress... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does surrogate endpoints compare with legacy clinician-rated or unharmonized outcome assessment instrument regarding overall survival and progression-free or disease-free survival over 48 month... | Can surrogate endpoints safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 48 months compared with legacy clinician-rated or unharmonized outcome assessment instrument for people with metas... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of surrogate endpoints for ... | measurement | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PIRD | Surrogate endpoints | Legacy clinician-rated or unharmonized outcome assessment instrument | 48 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Durer S et al., Schliemann A et al., Kong Y et al. & World Health Organization (WHO) Global Research Agenda | 2,025 | https://doi.org/10.1016/j.esmoop.2025.105843 | Durer S et al., ESMO open (2025); DOI: 10.1016/j.esmoop.2025.105843 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
End of preview. Expand in Data Studio
UnsolvedMedical (ulamai/UnsolvedMedical) — v3.0.0
MEDICAL DISCLAIMER — NOT CLINICAL OR PATIENT ADVICE: UnsolvedMed (
ulamai/UnsolvedMedical) is a scientific research dataset of unresolved medical, clinical, translational, and population-health research questions. It is NOT medical advice, a clinical decision support tool, a diagnostic device, a prescribing guide, or a substitute for professional healthcare judgment. Nothing in this dataset should be used to diagnose, treat, cure, or prevent any disease in an individual patient, or to alter any patient's medication or care plan.
1. Dataset Summary
UnsolvedMed (ulamai/UnsolvedMedical) v3.0.0 is a curated, provenance-rich, status-verified benchmark and research repository of 20,000 open and partially resolved medical problems (UMED-000001 to UMED-020000, published = true), accompanied by a stratified 2,000-problem Gold Seed (UMED-000001 to UMED-002000, is_gold_seed = true), a 500-problem executable AI benchmark (eval/benchmark_v3.jsonl), and 100 archived/withheld calibration and style-pack audit records (UMED-020001 to UMED-020100, published = false), totaling 20,100 canonical records.
Modeled as the medical sibling to ulamai/UnsolvedMath, UnsolvedMed v3.0.0 adapts open-problem curation to the epistemology of empirical medicine across 400 clinical sub-domains (20 per primary category) and 20 controlled question types:
- Paper-Native PICO & Condition-Coherent Outcomes: Every published problem extracts paper-verified condition/subtype, intervention/exposure/biomarker, comparator, and domain-coherent primary, safety, and patient-reported outcomes across 100 natural clinical research question formulations (
5 structural variants × 20 question types), paired with a concise 1-sentence core PICOclean_statementand patient-accessibleplain_language_statement. - 5-Source Provenance with Live ClinicalTrials.gov (
NCT0...) Linkage: Every published problem is backed by 5 distinct sources: 3 semantically co-cited peer-reviewed medical literature papers (problem_origin,openness_support, andpartial_resultwith real DOIs/PMIDs), 1 sub-domain-matched Tier A/B/C/D institutional consensus, guideline, or priority-setting status anchor (status_review), and 1 live registered clinical trial (NCT0...) harvested from the ClinicalTrials.gov API v2 (ongoing_research). - Compact & Self-Contained (
< 400 MB): Zero raw documents or verbatim source excerpts are stored; all fields (statement,clean_statement,plain_language_statement,background,why_open,known_partial_results,competing_hypotheses_or_interpretations,what_would_settle_it) are synthesized in our canonical UnsolvedMed format.
Release Highlights (v3.0.0)
| Metric | v1.0.0 | v1.5.0 | v2.0.0 | v3.0.0 (Current) |
|---|---|---|---|---|
Published Open / Partially-Resolved Problems (problems.json) |
10,000 | 15,000 | 20,000 | 20,000 (UMED-000001 – UMED-020000) |
Stratified Gold Seed Problems (data/gold/problems.jsonl) |
1,000 | 1,500 | 2,000 | 2,000 (UMED-000001 – UMED-002000, 10.0% per category) |
Executable AI Benchmark (eval/benchmark_v3.jsonl) |
— | — | — | 500 stratified Gold-Seed problems + 4 reference baselines |
Archived & Withheld Calibration Records (published = false) |
100 | 100 | 100 | 100 (UMED-020001 – UMED-020100) |
Total Canonical Records (dataset.json) |
10,100 | 15,100 | 20,100 | 20,100 |
| Clinical Sub-Domains & Question Formulations | 200 / 20 | 400 / 20 | 400 / 20 | 400 sub-domains / 100 natural question templates |
| Peer-Reviewed Literature Papers per Published Problem | 3 | 3 | 3 | 3 semantically co-cited papers (problem_origin, openness_support, partial_result) |
Live ClinicalTrials.gov (NCT0...) Registry Linkage |
— | — | — | 1,184 active/registered NCT0... trials (ongoing_research) |
| Total Sources per Published Problem | 4 | 4 | 4 | 5 (3 peer-reviewed papers + 1 Tier A–D status anchor + 1 NCT0... trial) |
Registered Provenance Sources (source_registry.json) |
23,071 | 28,532 | 30,289 | 29,175 (27,191 papers + 800 status anchors + 1,184 NCT trials) |
Explicit Problem Relations (relations/relations.jsonl) |
5,015 | 7,515 | 10,015 | 10,015 |
Immutable Status Events (history/status_events.jsonl) |
10,100 | 15,100 | 20,100 | 20,100 |
| Publication Gates Enforced | 18 / 18 | 18 / 18 | 18 / 18 | 18 / 18 (0 validation errors) |
2. Primary Medical Categories & Allocation Across v1.0, v1.5, and v3.0.0
| # | Primary Category | v1.0 (10k) | v1.5 (15k) | v3.0.0 (20,000) | Share | Gold Seed (v3.0.0) |
|---|---|---|---|---|---|---|
| 1 | Oncology and hematology (oncology_and_hematology) |
800 | 1,200 | 1,600 | 8.0% | 160 |
| 2 | Cardiovascular and cerebrovascular medicine (cardiovascular_and_cerebrovascular_medicine) |
600 | 900 | 1,200 | 6.0% | 120 |
| 3 | Neurology (neurology) |
600 | 900 | 1,200 | 6.0% | 120 |
| 4 | Mental health, behavioral health, and addiction (mental_health_behavioral_health_and_addiction) |
600 | 900 | 1,200 | 6.0% | 120 |
| 5 | Infectious diseases, tropical medicine, and antimicrobial resistance (infectious_diseases_tropical_medicine_and_amr) |
800 | 1,200 | 1,600 | 8.0% | 160 |
| 6 | Respiratory and sleep medicine (respiratory_and_sleep_medicine) |
400 | 600 | 800 | 4.0% | 80 |
| 7 | Endocrine, metabolic, obesity, and nutrition medicine (endocrine_metabolic_obesity_and_nutrition_medicine) |
500 | 750 | 1,000 | 5.0% | 100 |
| 8 | Gastroenterology, hepatology, and pancreatic disease (gastroenterology_hepatology_and_pancreatic_disease) |
400 | 600 | 800 | 4.0% | 80 |
| 9 | Kidney, urinary, and reproductive urology (kidney_urinary_and_reproductive_urology) |
360 | 540 | 720 | 3.6% | 72 |
| 10 | Immunology, rheumatology, and allergy (immunology_rheumatology_and_allergy) |
440 | 660 | 880 | 4.4% | 88 |
| 11 | Musculoskeletal medicine, orthopedics, pain, and dermatology (musculoskeletal_orthopedics_pain_and_dermatology) |
400 | 600 | 800 | 4.0% | 80 |
| 12 | Reproductive, maternal, and women’s health (reproductive_maternal_and_womens_health) |
500 | 750 | 1,000 | 5.0% | 100 |
| 13 | Pediatrics, neonatology, and adolescent medicine (pediatrics_neonatology_and_adolescent_medicine) |
500 | 750 | 1,000 | 5.0% | 100 |
| 14 | Aging, geriatrics, dementia care, and palliative medicine (aging_geriatrics_dementia_and_palliative_medicine) |
400 | 600 | 800 | 4.0% | 80 |
| 15 | Surgery, anesthesia, critical care, emergency medicine, and trauma (surgery_anesthesia_critical_care_emergency_and_trauma) |
500 | 750 | 1,000 | 5.0% | 100 |
| 16 | Diagnostics, imaging, pathology, laboratory medicine, and genomic medicine (diagnostics_imaging_pathology_laboratory_and_genomic_medicine) |
500 | 750 | 1,000 | 5.0% | 100 |
| 17 | Prevention, primary care, public health, and population medicine (prevention_primary_care_public_health_and_population_medicine) |
500 | 750 | 1,000 | 5.0% | 100 |
| 18 | Health services, implementation, quality, and patient safety (health_services_implementation_quality_and_patient_safety) |
400 | 600 | 800 | 4.0% | 80 |
| 19 | Rehabilitation, disability, sensory, oral, and communication health (rehabilitation_disability_sensory_oral_and_communication_health) |
400 | 600 | 800 | 4.0% | 80 |
| 20 | Rare, multisystem, and undiagnosed conditions (rare_multisystem_and_undiagnosed_conditions) |
400 | 600 | 800 | 4.0% | 80 |
| Total | All 20 Primary Medical Categories (400 Sub-Domains) | 10,000 | 15,000 | 20,000 | 100.0% | 2,000 |
3. Distribution by Question Type & Publication Class
3.1 Question Types (20,000 Published Records)
| Question Type | Count | Share |
|---|---|---|
classification |
1,002 | 5.0% |
diagnosis |
1,002 | 5.0% |
etiology |
1,002 | 5.0% |
mechanism |
1,002 | 5.0% |
natural_history |
1,002 | 5.0% |
prevention |
1,002 | 5.0% |
prognosis |
1,002 | 5.0% |
screening |
1,002 | 5.0% |
comparative_effectiveness |
1,000 | 5.0% |
safety |
1,000 | 5.0% |
treatment_effectiveness |
1,000 | 5.0% |
treatment_strategy |
1,000 | 5.0% |
health_services |
998 | 5.0% |
implementation |
998 | 5.0% |
measurement |
998 | 5.0% |
methodology |
998 | 5.0% |
patient_experience |
998 | 5.0% |
public_health |
998 | 5.0% |
rehabilitation |
998 | 5.0% |
supportive_palliative |
998 | 5.0% |
3.2 Publication Classes (All 20,100 Records)
| Publication Class | Count | Default Release Inclusion |
|---|---|---|
OPEN-VERIFIED |
8,000 | Yes (published = true) |
BLOCKED-OPEN |
4,000 | Yes (published = true) |
DISPUTED-OPEN |
4,000 | Yes (published = true) |
PARTIAL-PROGRESS |
4,000 | Yes (published = true) |
RESOLVED-IN-LITERATURE |
25 | No — Audit/Calibration (published = false) |
DUPLICATE |
15 | No — Audit/Calibration (published = false) |
NOT-A-MEDICAL-PROBLEM |
10 | No — Audit/Calibration (published = false) |
NOT-AN-OPEN-PROBLEM |
10 | No — Audit/Calibration (published = false) |
OBSOLETE-QUESTION |
10 | No — Audit/Calibration (published = false) |
UNANSWERABLE-AS-STATED |
10 | No — Audit/Calibration (published = false) |
OPEN-TRIAGE |
8 | No — Audit/Calibration (published = false) |
STATUS-UNCERTAIN |
7 | No — Audit/Calibration (published = false) |
RIGHTS-REVIEW |
3 | No — Audit/Calibration (published = false) |
SAFETY-REVIEW |
2 | No — Audit/Calibration (published = false) |
4. UnsolvedMedical-Bench v3.0 (AI Medical Research Evaluation Suite)
eval/benchmark_v3.jsonl provides a stratified 500-problem evaluation benchmark (25 Gold-Seed problems per primary medical category across all 20 question types) scored by scripts/evaluate_ai_benchmark.py across 4 tasks:
- Task 1 — Confirmatory Study Design Selection (
StudyMode F1): Predict the optimal settlement study modes (what_would_settle_it.preferred_study_modes). - Task 2 — Epistemic Evidence-Gap Root-Cause Diagnosis (
Gap F1): Identify the primary reason the clinical question remains unsettled (why_open.primary_reasons). - Task 3 — Structured PICO & Endpoint Protocol Specification (
PICO Score): Reconstruct the target intervention, comparator, primary endpoint, and follow-up horizon. - Task 4 — Competing Mechanistic / Clinical Hypothesis Discrimination (
Hyp Acc): Discriminate the genuine competing clinical interpretation from domain-matched distractors.
Reference Baseline (eval/benchmark_summary.json) |
Composite Score | StudyMode F1 | Gap F1 | PICO Score | Hyp Acc |
|---|---|---|---|---|---|
uninformed_rct_majority_baseline |
20.50 | 32.00 | 0.00 | 25.02 | 23.25 |
lexical_clinical_heuristic_baseline |
41.58 | 37.68 | 13.84 | 60.62 | 58.30 |
domain_neighbor_retrieval_baseline |
61.16 | 58.40 | 52.40 | 51.79 | 87.95 |
oracle_reference_upper_bound |
100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
5. Repository Layout & Compatibility
UnsolvedMed matches the compact, clean repository structure of ulamai/UnsolvedMath:
- Root UnsolvedMath-compatible JSONs:
problems.json— 20,000 published open/partially-resolved medical problems (published = true)dataset.json— All 20,100 canonical records (including 100 calibration/archived/withheld records)research_results.json— Structured literature and status assessments for all 20,100 recordssource_registry.json— 29,175 provenance sources (papers, guidelines, andNCT0...trials) with DOIs, PMIDs, tiers, and license metadatastatement_audit.json— Statement quality, rights, and safety review recordsstatistics.json,categories.json,difficulty_levels.json,sets.json
- Parquet, Benchmark & Canonical Tables:
releases/unsolvedmed_current.parquet(v3.0.0: 20,000 published records) &releases/unsolvedmed_v1_5_current.parquet(v1.5: 15,000 published records)eval/benchmark_v3.jsonl&eval/benchmark_summary.json(500-problem AI medical research benchmark & reference baselines)data/gold/problems.jsonl(2,000 Gold Seed records)relations/relations.jsonl(10,015 problem relations)history/status_events.jsonl(20,100 status events)schemas/*.schema.json,ontology/*.yaml,taxonomy/*.yaml,prompts/*.md,docs/*.md
6. Quickstart Usage
import json
import pyarrow.parquet as pq
# Load v3.0.0 (20,000 problems) via Parquet
table = pq.read_table("releases/unsolvedmed_current.parquet")
print("Published problems in Parquet:", table.num_rows)
# Load Gold Seed (2,000 clinician + methodologist verified records)
with open("data/gold/problems.jsonl", "r", encoding="utf-8") as f:
gold_seed = [json.loads(line) for line in f]
print("Gold Seed records:", len(gold_seed))
print("Sample question:", gold_seed[0]["id"], "->", gold_seed[0]["statement"])
print("Clean PICO statement:", gold_seed[0]["clean_statement"])
print("Active registered trials:", gold_seed[0]["status_assessment"]["active_research"])
7. Licensing, Provenance & Responsible Release
- Dataset Metadata, Taxonomy & Newly Authored Canonical Paraphrases: Licensed under CC BY 4.0 (
LICENSE). - Source Reuse Policy: All canonical titles, statements, backgrounds, and evidence-gap syntheses are newly written in house style. Zero raw documents or verbatim source excerpts are redistributed.
- Safety & Ethics: Every published record passed Gate 17 (Ethics, Safety, and Non-Harm), ensuring zero patient-identifiable data, zero individualized clinical advice framing, and zero actionable dual-use biological hazard details.
- Downloads last month
- 159